SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (16727)3/11/2004 8:42:28 PM
From: Robert K.  Read Replies (1) | Respond to of 17367
 
You do realize I hope that that ALSO means that the use of Enbrel might be superior when used with Raptiva and vice versa. That means (if holds true), that BOTH will enjoy ENORMUS use in psoriasis and perhaps beyond. DUAL therapy.
Genentech holding this patent can only help. This could kill the notion of which drug will get the most market share. Duh.
Oh, and wait till citibank and the ilk take the reins.
skd


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News